PSU Profiles
Loading...
Keywords
Last Name
Institution

Sheldon L. Holder

TitleAssistant Professor
InstitutionCollege of Medicine
DepartmentMedicine
Address500 University Drive Hershey, PA 17033
Phone717-531-0003 ext 289532
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Education:

    Fellowship, Hematology/Oncology, Vanderbilt University, 2013
    Residency, Internal Medicine, Penn State M. S. Hershey Medical Center, 2010
    Medical School (MD), Loma Linda University, 2007
    Graduate School (PhD), Microbiology and Molecular Genetics, Loma Linda University, 2005


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Small J, Washburn E, Millington K, Zhu J, Holder SL. The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. Oncotarget. 2017 Nov 10; 8(56):95116-95134. PMID: 29221116.
      View in: PubMed
    2. Joshi M, Vasekar M, Grivas P, Emamekhoo H, Hsu J, Miller VA, Stephens PJ, Ali SM, Ross JS, Zhu J, Warrick J, Drabick JJ, Holder SL, Kaag M, Li M, Pal SK. Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. Oncotarget. 2016 Aug 09; 7(32):52442-52449. PMID: 27213592.
      View in: PubMed
    3. Joshi M, Millis SZ, Arguello D, Holder SL, Lamm D, Reddy S, Belani C, Drabick JJ, Vogelzang NJ. Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. Eur Urol Focus. 2016 Jun 24. PMID: 28753770.
      View in: PubMed
    4. Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016 06; 21(6):708-15. PMID: 27053504; PMCID: PMC4912364 [Available on 06/01/17].
    5. Al-Marrawi MY, Mackley HB, Ali S, Wagner H, Joshi M, Holder S, Kaag M, Mallon C, Talamo G, Drabick JJ. Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review. Clin Genitourin Cancer. 2016 08; 14(4):e393-9. PMID: 26877063.
      View in: PubMed
    6. Al-Marrawi MY, Holder SL. Current Immunotherapies for Renal Cell Carcinoma. Curr Mol Pharmacol. 2016; 9(3):252-263. PMID: 26177641.
      View in: PubMed
    7. Yin M, Wang W, Rosenberg J, Kaag M, Joshi M, Holder S, Tuanquin L, Drabick JJ. Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review. Clin Genitourin Cancer. 2016 Apr; 14(2):e203-6. PMID: 26684811.
      View in: PubMed
    8. Wang W, Cheng J, Mallon C, Al-Marrawi MY, Holder S, Joshi M, Kaag M, Talamo G, Drabick JJ. Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review. Clin Genitourin Cancer. 2015 Dec; 13(6):e391-5. PMID: 26303589.
      View in: PubMed
    9. Al-Marrawi MY, Cream LV, Mallon CA, Holder S, Joshi M, Harvey HH, Talamo G, Drabick JJ. Effect of topical vaginal androgens in a woman on the testosterone levels of her sexual partner with prostate cancer. J Clin Oncol. 2015 Feb 10; 33(5):521-2. PMID: 25559812.
      View in: PubMed
    10. Lipkin JS, Rizvi SM, Gatalica Z, Sarwani NE, Holder SL, Kaag M, Drabick JJ, Joshi M. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Cancer Biol Ther. 2015; 16(1):28-33. PMID: 25692619; PMCID: PMC4622500.
    11. Holder SL, Drabick J, Zhu J, Joshi M. Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer. Cancer Biol Ther. 2015; 16(2):207-9. PMID: 25756508; PMCID: PMC4622618.
    12. Holder SL, Abdulkadir SA. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance. Curr Cancer Drug Targets. 2014; 14(2):105-14. PMID: 24274399.
      View in: PubMed
    13. Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem. 2007 Oct 01; 15(19):6463-73. PMID: 17637507.
      View in: PubMed
    14. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007 Jan; 6(1):163-72. PMID: 17218638.
      View in: PubMed
    15. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67. PMID: 12954615.
      View in: PubMed
    Holder's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _